Simulations Plus Inc. (NASDAQ: SLP) announced a technical collaboration with NVIDIA to develop GPU-accelerated simulation and AI-assisted workflows for drug development modeling applications.

The partnership combines Simulations Plus' scientific engines for physiologically-based pharmacokinetics, pharmacokinetics/pharmacodynamics, and quantitative systems pharmacology with NVIDIA's AI infrastructure. The collaboration aims to accelerate simulation cycles and enable large-scale exploration of model structures and parameters.

NVIDIA will contribute computing infrastructure and expertise in accelerated inference and GPU optimization to improve simulation performance. The company also provides access to its BioNeMo platform and pharmaceutical partner network.

The collaboration focuses on three areas: developing GPU-optimized simulation capabilities, creating AI-assisted scientific workflows, and advancing quantitative systems pharmacology applications. Testing shows up to a 75% reduction in time required for end-to-end quantitative systems pharmacology modeling, according to the press release.

"Our collaboration with NVIDIA brings together validated science, accelerated computing, and AI capabilities in a way that expands what scientific teams are able to explore and accomplish," said Shawn O'Connor, Chief Executive Officer of Simulations Plus.

The companies plan to engage pharmaceutical partners to evaluate these capabilities in drug development workflows, with initial focus on high-complexity modeling use cases.

"By bringing NVIDIA accelerated computing and AI infrastructure together with Simulations Plus' deep expertise in model-informed drug development, we can help researchers run more complex models, explore larger design spaces, and move from insight to decision faster," said Anthony Costa, Director of Digital Biology and Health at NVIDIA.

Simulations Plus develops software and consulting solutions for pharmaceutical discovery, development, and commercialization.